Lab marker

ApoB

Apolipoprotein B · ApoB-100

The single most informative blood marker for cardiovascular risk, counts every atherogenic particle, not just the cholesterol they carry.

Strong relevance8 cited sourcesNo fasting€10–30 private; usually covered when ordered by a physician for cardiovascular risk assessment.nutritionmovement

What it measures

ApoB is a structural protein found on every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a), chylomicron remnants). Because each particle carries exactly one ApoB, the test counts particles directly. LDL-C, by contrast, measures the cholesterol cargo: two people with the same LDL-C can have very different particle counts, and particle count predicts events more accurately than cholesterol content.

Reference context

4 guideline sources

Laboratory reference ranges typically report 'normal' up to ~120–130 mg/dL based on population distribution. Population-typical is not the same as optimal; most epidemiological evidence supports lower-is-better down to ~40 mg/dL for atherosclerotic risk.

Population context: consult guideline targets below

Mechanism

Why moving this marker matters

Atherosclerosis is initiated by ApoB-containing particles entering and being retained in the arterial wall. Particle number is the proximal driver of plaque progression; cholesterol cargo is a downstream consequence. Mendelian randomisation across multiple cohorts has shown that lifelong lower ApoB causally reduces coronary disease risk.

Guideline targets

What major guidelines recommend

ESC/EAS 2019 (moderate CV risk)

Strong

<100 mg/dL

ESC/EAS 2019 (high CV risk)

Strong

<80 mg/dL

ESC/EAS 2019 (very-high CV risk)

Strong

<65 mg/dL

AACE 2017 (high risk)

Moderate

<90 mg/dL

How to measure

The test, where to get it, when to repeat

Method

Standard blood draw, non-fasting acceptable. Most modern labs report in mg/dL.

Where

Through your GP, or directly via private lab providers in most markets (Medichecks, Thriva, Quest, Labcorp, Synlab).

Typical cost

€10–30 private; usually covered when ordered by a physician for cardiovascular risk assessment.

Fasting

Not required

When to test

  • ESC/EAS 2019 dyslipidaemia

    ApoB is recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity or very low LDL-C.

  • AACE/ACE 2017

    Use ApoB alongside or instead of LDL-C for risk stratification, particularly with metabolic syndrome or hypertriglyceridaemia.

  • NLA 2014

    Reasonable secondary target after LDL-C in high-risk patients.

Where to test

Independent labs offering this test

Healicus refers you to independent laboratories. You order from the lab; they take the sample, run it, and return your result on their own platform. Healicus never sees your value.

Healicus is not the provider. Your contract for the service is with whoever you choose. Links labelled Sponsored are paid affiliate relationships; unlabelled links are editorial reference only. See our disclosure for the full policy.

Context

Reading the numbers

Laboratory reference ranges typically report 'normal' up to ~120–130 mg/dL based on population distribution. Population-typical is not the same as optimal; most epidemiological evidence supports lower-is-better down to ~40 mg/dL for atherosclerotic risk.

Caveats

Assay variation is small (<5%). Levels are stable across the day and largely unaffected by recent meals, unlike triglycerides.

Practices

What's been shown to influence this marker

PREDIMED (NEJM 2018): a Mediterranean diet supplemented with extra-virgin olive oil or nuts led to fewer major cardiovascular events than a reduced-fat control diet. The trial did not report ApoB, so any effect on ApoB itself is not established.

In REDUCE-IT, high-dose EPA (icosapent ethyl 4 g/day) lowered triglyceride-rich lipoproteins. This is a prescription medicine, not fish-oil supplements; lower-dose fish oil has smaller effects. High-dose omega-3 carries a dose-dependent atrial-fibrillation risk (EMA PRAC 2023).

Mediterranean dietary patternHabit
Moderate evidence

Mediterranean dietary pattern

Olive oil, fish, nuts, legumes, plants. Two randomised trials found fewer major cardiovascular events than a low-fat diet.

Read full evidence

Why

The Mediterranean pattern, heavy on plants, olive oil, fish, nuts, legumes; moderate fish and dairy; light on red meat, has randomised-trial evidence for fewer major cardiovascular events than a low-fat diet in adults at high cardiovascular risk. PREDIMED, the largest trial (republished after protocol deviations), showed ~30% fewer major cardiovascular events vs. low-fat control. Trial evidence for cognition is thin.

Slot in your day

With a meal

How to do it

How

Olive oil as the primary fat. Plants at every meal. Fish 2–3× per week. Nuts daily (small handful). Red meat once a week or less. Alcohol is not needed for the pattern; low-volume drinking has not been shown to be protective.

Sticking with it

Stock the kitchen for one week's pattern. Decisions live in the shopping list, not at mealtime.

Markers this may influence

Evidence

At a glance

Estruch 2018 N Engl J Med RCT (n=7,447, adults at high cardiovascular risk, republished after protocol deviations): a Mediterranean diet with olive oil or nuts had fewer major cardiovascular events than a control diet advising less fat (hazard ratios 0.69 and 0.72). Delgado-Lista 2022 Lancet RCT (n=1,002, coronary heart disease) found a similar direction versus a low-fat diet, mainly in men. Trial evidence for cognition is thin.

GRADE certainty: Moderate — rated by Healicus using the GRADE method (RCT evidence; downgraded for protocol deviations/no blinding in the main trials and for indirectness of dietary-pattern comparisons)

Omega-3 (EPA + DHA)CautionSupplement
Strong evidence
Within weeks

Omega-3 (EPA + DHA)

EPA and DHA contribute to the normal function of the heart at a combined intake of at least 250 mg/day (EU authorised claim). Not needed by people who eat fatty fish twice or more a week.

Read full evidence

Why

EPA and DHA are long-chain omega-3 fatty acids primarily from fatty fish. They support cell membrane function and are concentrated in brain tissue. NICE advises against omega-3 compounds to prevent cardiovascular disease. Supplements are an option for people who don't eat fatty fish regularly. Algae-derived versions exist for vegetarians.

How it works

Incorporated into cell membranes; competes with arachidonic acid in eicosanoid synthesis, shifting inflammatory signalling toward resolution.

Expected onset · ~12 weeks for steady-state membrane uptake

How to take

Dosage

1–2g combined EPA+DHA daily (check the label, total fish oil weight is misleading).

Timing

With a meal containing fat

On the label

Look for combined EPA+DHA per serving on the label, not just 'fish oil 1000mg'. Third-party tested for purity (IFOS, USP).

Studied in

People who eat fatty fish less than twice a week.

Safety

Mild blood-thinning effect; discuss with a doctor if on anticoagulants. The EMA's safety committee (2023) added atrial fibrillation as a common, dose-dependent side effect of prescription omega-3 medicines, with the highest risk at 4 g a day. Fish allergy: fish-oil products are unsuitable.
Loading interactions…

Markers this may influence

Evidence

At a glance

EU authorised claim: EPA and DHA contribute to the normal function of the heart, at a combined intake of at least 250 mg a day. NICE guideline NG238 (2023) advises against offering omega-3 fatty acid compounds to prevent cardiovascular disease, with a narrow exception for icosapent ethyl added to statins in people with raised triglycerides, so the claim covers normal function, not disease prevention.

GRADE certainty: High — EU authorised claim

See also

Related markers

Take to your physician

Worth discussing

  • Whether ApoB or LDL-C is more useful given your risk profile.
  • If ApoB and LDL-C disagree (common with metabolic syndrome), which to target.
  • Whether your absolute ApoB warrants discussion of lifestyle, lifestyle plus pharmacotherapy, or pharmacotherapy directly.

Sources

Cited literature

Last reviewed October 2026

Educational reference. Population-level information for the longevity-curious reader. Healicus does not compute scores, interpret your specific values, or produce personalised recommendations from your clinical data. Discuss your own results and any decisions with your physician.

Keep reading